Press Release : US FDA approves Roche's Tecentriq -2-

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] World Health Organization: GLOBOCAN 2020 -- Lung Cancer: Estimated cancer incidence, mortality and prevalence worldwide. [Internet; cited September 2021] Available from: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

[2] American Cancer Society: What Is Lung Cancer? [Internet; cited September 2021] Available from: https://www.cancer.org/cancer/lung-cancer/about/what-is.html

[3] EpiCast report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016. [Internet; cited September 2021] Available from: https://store.globaldata.com/report/gdhcer132-16--epicast-report-non-small-cell-lung-cancer-nsclc-epidemiology-forecast-to-2025/

[4] Yano T, et al. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 2014;5(5):1048-54.

Roche Group Media Relations

Phone: [phone] / e-mail: [e-mail] https://www.globenewswire.com/Tracker?data=BzcHVw2FrciB9cr7KIK02g5z_aVvbQ1XWdKWX02UTJqFR5a6YpTdifW-atj8AjPZNRFqZZQZZw1PZCSL7tzaWzVs4reveADMS84vOSMjvHsX_MU6DGZ4yNQrr3EY3ZZK

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
 Sileia Urech 
 Phone: [phone] 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: [e-mail] 
 [e-mail] 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: [e-mail] 
 [e-mail] 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: [phone] 
 e-mail: mailto:[e-mail] 
 [e-mail] 
-------------------------------------------- 
 

Attachment

   -- 15102021_MR_Tecentriq_adjuvant_IMpower010_en 
      https://ml-eu.globenewswire.com/Resource/Download/0c048259-6bc4-4419-b3c3-194bc8e51bbc

(END) Dow Jones Newswires

October 15, 2021 12:30 ET (16:30 GMT)